Nanobac Pharmaceuticals, Incorporated (NNBP)
Nanobac Pharmaceuticals, Incorporated operates in the Biotechnology industry of the Healthcare sector, headquartered in Tampa, FL, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $24,951. On trailing twelve-month figures it carries a trailing P/E of 0.00, a net margin of -37319.7%. Its beta of -8.83 implies it has historically moved less than the broad market.
Nanobac Pharmaceuticals, Incorporated is dedicated to advancing human health through the creation and refinement of products and services designed for the identification and management of calcifying nanoparticles (CNPs). The company's offerings include the production and sale of in vitro diagnostic (IVD) kits, which encompass assays, antibodies, and reagents specifically developed for detecting CNPs. Notably, their diagnostic assays include NANO-CAPTURE and NANO-SERO. Furthermore, Nanobac engages in research and clinical studies focused on various urological diseases—such as chronic prostatitis/chronic pelvic pain syndrome, kidney stones, and polycystic kidney diseases—as well as cardiovascular ailments. Established in 1994 and headquartered in Tampa, Florida, the company operated as HealthCentrics Inc. until its name change to Nanobac Pharmaceuticals, Incorporated in December 2002.
Nanobac Pharmaceuticals, Incorporated is most often compared with the following Healthcare names: